Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on April 26, 2022. The report details the completion of a Registered Direct Offering and a concurrent Private Placement of warrants.
Key Financial Metrics
- Gross Proceeds: Approximately $2.3 million.
- Common Stock Sold: 9,339,436 shares at $0.25 per share.
- Warrants Sold: 7,004,578 warrants (75% of shares sold) with an exercise price of $0.3399 per share.
- Net Proceeds: Not explicitly stated; gross proceeds are before deducting placement agent fees and transaction expenses.
- Use of Proceeds: General corporate purposes, working capital, and advancing the preclinical and clinical pipeline.
Material Changes
The filing reports the finalization of a capital raise transaction initiated on April 22, 2022. This represents a significant increase in cash liquidity for the company, though specific pre-transaction cash balances or debt levels are not disclosed in this document.
Outlook and Management Commentary
Management intends to utilize the net proceeds to support the company's operational needs and advance its drug development pipeline. The filing includes a legal opinion from Hogan Lovells US LLP regarding the legality of the issuance.
Investor Verification Checklist
- Verify the exact amount of net proceeds after deducting placement agent fees and transaction expenses.
- Confirm the current cash position and runway of Salarius Pharmaceuticals, Inc. post-transaction.
- Review the specific terms of the warrants, including expiration dates and exercise conditions, which are not detailed in this summary.
- Check for any subsequent filings regarding the dilution impact of the 9.3 million shares issued.